Compare COF & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COF | BDX |
|---|---|---|
| Founded | 1988 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8B | 55.1B |
| IPO Year | 1994 | 1962 |
| Metric | COF | BDX |
|---|---|---|
| Price | $237.46 | $201.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $252.12 | $212.13 |
| AVG Volume (30 Days) | ★ 4.0M | 2.0M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | 1.34% | ★ 2.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.38 | ★ 5.82 |
| Revenue | ★ $28,886,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $96.76 | $4.00 |
| Revenue Next Year | $18.32 | $3.40 |
| P/E Ratio | $99.92 | ★ $34.52 |
| Revenue Growth | ★ 9.02 | 8.24 |
| 52 Week Low | $143.22 | $162.29 |
| 52 Week High | $243.31 | $251.99 |
| Indicator | COF | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 65.48 |
| Support Level | $228.63 | $188.52 |
| Resistance Level | $243.31 | $196.12 |
| Average True Range (ATR) | 5.37 | 3.53 |
| MACD | 2.35 | 0.70 |
| Stochastic Oscillator | 84.15 | 88.65 |
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending still provides the majority of the bank's revenue.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.